NuVasive — Q4 2016 Earnings Presentation
15 slides from NuVasive's earnings presentation, Feb 9, 2017
Slide 1: Q4/Full Year 2016 Results Supplemental Presentation to Earnings Press Release
Q4/Full Year 2016 Results Supplemental Presentation to Earnings Press Release February 9, 2017 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could caus
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting adjustments on acq
Slide 4: Q4 & Full Year 2016 Performance
Q4 & Full Year 2016 Performance Reported year-over-year revenue growth of 25.9% to $271.1 million, or 25.5% on a constant currency basis. Delivered GAAP operating profit margin of 11.1%; non-GAAP operating profit margin of 18.0%, up 90 bps from prior year. Drove GAAP diluted earnings per share of $0
Slide 5: Fourth Quarter 2016 Revenue Highlights
Fourth Quarter 2016 Revenue Highlights 22% U.S. SPINAL HARDWARE Includes All Implants, Fixation, MAGEC® & PRECICE® 26% 42%* * Constant currency basis U.S. SURGICAL SUPPORT Includes Biologics, IOM Services & Disposables INTERNATIONAL Includes Puerto Rico Key Performance Factors Continued Adoption of
Slide 6: NUVA 2016 Highlights
PROFITABILITY STRATEGY CAPITAL DEPLOYMENT New state-of-the-art manufacturing facility online New international headquarters Settled 8 year litigation with Medtronic Improved asset efficiencies Established $150M revolving credit facility Issued $650M Convertible Senior Notes due 2021 Repurchased $339
Slide 7: Q4 & Full Year 2016 P&L Performance
Q4 & Full Year 2016 P&L Performance OPERATING LEVERAGE STORY CONTINUES TO PLAY OUT 75.3% 76.6% 52.5% 55.5% 4.8% 5.0% 18.0% 16.1% $0.53 $1.66 26.8% 25.2% NON-GAAP MEASURES Gross Margin SM&A R&D Operating Profit Margin EPS Adjusted EBITDA Margin 4Q16 ACTUALS 4Q16 YOY PERFORMANCE FACTORS FY16 ACTUALS F
Slide 8: Strong History of Growth and Profitability
* NuVasive financial performance guidance as of February 9, 2017. Global Revenue (In Millions) Non-GAAP Operating Profit Margin ~570 Basis Point Improvement $1,065* 11.4% 15.4% 16.1% 17.1%* Strong History of Growth and Profitability DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS
Slide 9: Investment in U.S. Manufacturing
New ‘all digital’, 180,000 sq. ft. facility is on-line and supporting select implants and instruments Began manufacturing first products out of facility in Q3 2016 Investing ~$45M to construct and equip new facility with state-of-the-art equipment Expect to employ ~300 high-tech positions Further al
Slide 10: Driving ~20% CAGR in Adjusted EBITDA Improvements
Driving ~20% CAGR in Adjusted EBITDA Improvements * NuVasive financial performance guidance as of February 9, 2017. Incremental focus on improving the working capital profile and CapEx spending will drive incremental gains in the free cash flow profile of the company. Disciplined approach to driving
Slide 11: Driving Improved Tax Rate
Driving Improved Tax Rate Focused on reducing tax rate through international scale and domestic tax planning Opportunity to drive non-GAAP effective tax rate lower by ~1,400 bps over 5 years. OPERATING IMPROVEMENTS TAKING HOLD Global tax planning initiatives are playing through: International scale
Slide 12: FY17 Guidance
* NuVasive financial performance guidance as of February 9, 2017; ^Constant currency FY17 Guidance Performance Drivers Revenues As reported ~$1.065B, ~11.7% YoY growth^ ~$61M full year of Biotronic contribution; ~$10M currency headwind U.S. Spinal Hardware U.S. Surgical Support International ~8% YoY
Slide 13: Q1 2017 Performance Expectations
Q1 2017 $250M Revenue Non-GAAP operating profit margin of 14.1% Q1 2017 Performance Expectations* PERFORMANCE EXPECTATIONS FOR MODELING PURPOSES 3 ~16.4% Reported Ex FX ~6.7% Pro-forma Ex FX Non-GAAP Earnings per share of $0.37 * NuVasive financial performance guidance as of February 9, 2017; growth
Slide 14: Why Invest in NuVasive
Growing revenues at multiples of market in high single-digit range* Long-term non-GAAP operating profit margins expanding to ~25% and adjusted EBITDA margin to ~32%* Drive change in tax rate from high 30%’s to high 20%’s* Optimizing tax structure to drive EPS growth 2x the rate of revenue growth* Se
Slide 15: Slide 15